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Introduction
Whole-grain (WG) 9 foods have been suggested to reduce the risk of cardiovascular diseases (1-3), certain cancers (4), and type 2 diabetes (1, 2) . According to epidemiologic data, even 1-3 servings/d (i.e., 16-48 g) of WG is associated with health benefits (3, 4) . For this reason, in the United Kingdom, the Balance of Good Health recommends that 1/3 of food intake should be based on bread, cereals, and potatoes, and consumers should select WG varieties where possible (5) . However, most individuals consume <1 serving/d and ;30% do not eat any WG foods whatsoever (6) . This is due to lack of understanding of the relative health benefits of WG foods, preconceived negative perception of the taste of WG foods, and difficulty in identifying WG products (7, 8) .
Some cross-sectional and prospective studies have associated increased WG consumption with lower BMI, weight, and weight gain, and smaller waist circumference (1, (9) (10) (11) . In clinical trials, however, most studies show no effects on body weight, BMI, waist circumference, or body fat content (12) (13) (14) , although Andersson et al. (15) reported an increase in BMI after a 6-wk WG intervention. Davy et al. (16) and Carvalho-Wells et al. (12) observed no changes in blood pressure (BP) after 12-wk consumption of high-fiber oat or wheat cereal and 3-wk consumption of a maize WG cereal, respectively. However, other studies reported reductions in BP after 6 or 12 wk of WG wheat, wheat and oats, or oat interventions (17) (18) (19) .
Although some cross-sectional studies demonstrate an inverse association between WG intake and fasting glucose (1), total cholesterol (TC), and LDL cholesterol (9) , other studies demonstrate no effect on blood lipids (1) or glucose (20) . A systematic review of 10 controlled interventions concluded that consumption of WGs (in the form of oats in 8 studies) decreased plasma concentrations of TC and LDL cholesterol, but not HDL cholesterol or TG (21) . Moreover, a meta-analysis of 21 randomized controlled trials reported significantly lower concentrations of fasting glucose, TC, and HDL cholesterol after WG interventions (22) . However, individual studies are inconsistent and at times show limited or no effects of WG consumption on blood lipids and glucose in both healthy adults and adults with metabolic conditions (12-15, 17, 23, 24) .
The aim of the current study was to assess the feasibility of achieving increased intakes of WG (at least 80 g/d) in lowhabitual consumers and to investigate the impact of increased WG consumption on body composition, blood lipid and glucose profiles, colonic microbiology, and gut health, checking compliance to the diet with use of plasma alkylresorcinols as biomarkers of WG intake (25, 26) .
Methods
Subjects. Thirty-three healthy subjects (12 men, 21 women), aged 40-65 y (mean age: 48.8 y), with habitual WG consumption <24 g/d and BMI 20-35 kg/m 2 , were recruited into the study ( Table 1) . Exclusion criteria included diagnosed diabetes, heart disease, stroke, vascular disease, inflammatory disease, renal, bowel, liver, or pancreatic disease, medication for hyperlipidemia, hypertension, hypercoagulation, inflammatory conditions or depression, prescribed aspirin, asthma, allergies, smoking, excessive consumption of alcohol (>21 or 15 units/wk for men and women, respectively), planned influenza vaccination or vaccination during the previous 12 mo, consumption of prebiotics or probiotics, or antibiotic treatment during the previous 3 mo. The study was approved by the University of Reading Research and Ethics Committee (ISRCTN36521837).
Recruitment. Potential subjects responding to advertisements were sent an information sheet and those who were interested in participating completed a medical and lifestyle questionnaire. Subjects consuming <24 g/d of WG were identified through use of an FFQ, which was modified from Ross et al. (27) for use in the United Kingdom (48 items, 8 frequencies). Suitable subjects were then invited to the Hugh Sinclair Unit of Human Nutrition (University of Reading, United Kingdom) for a screening visit where informed consent was obtained before measuring height, weight, waist circumference, and BP, and collecting blood for a full blood count ( Figure 1 ).
Study design. During a 2-wk run-in period, the habitual diet of the subjects was assessed in more detail through use of 3-day food diaries (3DFDs), which were also used to provide tailored advice to achieve the WG target intakes. In consultation with a dietitian, subjects were advised to consume a diet high in WGs (>80 g/d) or low in WGs (<16 g/d, RG diet) in a crossover study, with intervention periods lasting 6 wk each, separated by a 4-wk washout period ( Figure 2 ). Random assignment was based on age, gender, and BMI. Commercially available pasta, rice, snacks, and breakfast cereals in both the WG and RG categories were provided to volunteers every fortnight and advice was given about substitution of habitually consumed products. Bread from a pre-agreed list was purchased by subjects and costs reimbursed upon production of Tables 1 and 2 ). While on the study, subjects did not consume prebiotics or probiotics and, during each of the 2 intervention periods, completed a 3DFD and kept a daily record of consumption of the provided foods [dietary compliance diary (DCD)]. They were also asked to record the presence and severity of 6 gastrointestinal symptoms on a daily basis and any adverse effects experienced or medication taken. Food diaries were analyzed with use of Dietplan6 (Forestfield Software Ltd.). Fasting blood and fecal (24 h and fresh) samples were collected, and anthropometric and BP measurements were performed at the beginning and end of each of the intervention periods. Three months after their last visit, subjects were asked to complete a poststudy questionnaire about their attitude toward WG and RG foods and any changes to their habitual diet since completing the study.
receipts (Supplemental
Blood collection, plasma and serum separation, and storage. Blood was collected in EDTA K 3 tubes and Serum Sep Clot Activator tubes. Plasma and serum samples were frozen at 220°C within 1 h of collection.
Alkylresorcinol analysis. Plasma alkylresorcinols were analyzed using a modification of a normal-phase LC/tandem MS method (28) after extraction with diethyl ether. The modification entailed the use of a shorter column (100 mm 3 2 mm instead of a 250 mm 3 2 mm column) with subsequent shortening of the chromatographic run time from 15 min to 8 min. Results did not differ for samples analyzed with use of the updated method compared to the new method. Matrix-matched calibration was used, and 2 control samples were run in triplicate with each batch. Control samples and calibration curve standards were run in random order throughout each sequence. Intrabatch repeatability for each control plasma sample was <10% and interbatch repeatability was <15%.
Biochemical markers. Plasma lipids and glucose were measured with use of an ILab 600 automatic analyzer and enzyme-based kits and quality controls (Instrumentation Laboratory, Cheshire, United Kingdom and Alpha Laboratories, Hampshire, United Kingdom). Controls were run with each batch and their values were within the specified range. All samples for each subject were analyzed within a single batch (interassay mean CV = 1.6%).
Anthropometrics and BP. Height, weight, body fat percentage, waist circumference, and BP were measured at screening and at the beginning and end of the 2 intervention periods. Impedancemetry (Tanita BC-418MA) was used to determine weight and body fat content. BP reported at each visit was the mean of 3 measurements (mean CV = 3.6%).
Collection and processing of fecal samples. Twenty-four-hour fecal samples were collected during the day before the visit, whereas fresh fecal samples were collected on the morning of the visit and kept under anaerobic conditions (Oxoid, Hampshire, United Kingdom) for a maximum of 2 h until processing. Samples were prepared for fluorescence in situ hybridization (FISH) and SCFA analysis as described previously (12) . To measure fecal water content, ;2 g of fresh fecal sample was dried for 25 h at 70°C. FISH analysis. Synthetic oligonucleotide probes, labeled with the fluorescent dye Cy3 (Sigma-Aldrich) were used for the enumeration of different bacterial groups. Specific regions of the 16S rRNA gene of total bacteria were targeted with use of a mixture of EUB338, EUB338II, and EUB338III probes (with 5# to 3# sequences GCT-GCC-TCC-CGT-AGG-AGT, GCA-GCC-ACC-CGT-AGG-TGT, and GCT-GCC-ACC-CGT-AGG-TGT, respectively) in equimolar concentrations at hybridization and washing temperatures of 46°C and 48°C, respectively (29) . The rest of the bacterial groups enumerated were (probe name, targeted molecule, 5# to 3# sequence, hybridization temperature, washing temperature, reference) Clostridium coccoides/Eubacterium rectale group, Erec482, 16S rRNA, GCT-TCT-TAG-TCA-RGT-ACCG, 50°C, 50°C (30); Bifidobacterium genus, Bif164, 16S rRNA, CAT-CCG-GCA-TTA-CCA-CCC, 50°C, 50°C (31); Lactobacillus-Enterococcus group, Lab158, 16S rRNA, GGT-ATT-AGC-AYC-TGT-TTC-CA, 50°C, 50°C (32); Bacteroides-Pevotela group, Bac303, 16S rRNA, CCA-ATG-TGG-GGG-ACC-TT, 46°C, 48°C (33); Clostridium histolyticum group, Chis150, 16S rRNA, TTA-TGC-GGT-ATT-AAT-CTY-CCT-TT, 50°C, 50°C (30); and Escherichia coli, EC1531, 23S rRNA, CAC-CGT-AGT-GCC-TCG-TCA-TCA, 37°C, 37°C (34) . FISH analysis was performed according to the method described by Salazar et al. (35) 
(Supplemental Methods).
Fecal SCFA analysis. Supernatants were defrosted, centrifuged at 7500 3 g for 5 min, and filtered through 0.2-mm polyvinylidine fluoride filters (GE Healthcare Life Science). A total of 1 mol/L formic acid and 1 mmol/L 2-ethylbutyric acid were added as an internal standard (IS) at a ratio of 1:5 (vol:vol, IS:sample), and acetic, propionic, butyric, isobutyric, valeric, isovaleric, and caproic acids were used as external standards and mixed with the IS (1:5 ratio of IS:external standard). Samples were analyzed (with a split injection ratio of 5:1) in a 5890 Series II GC system fitted with a Nukol capillary column (Supelco, FS CAP NUKOL 30 m 3 0.53 mm 3 1.0 mm; Sigma-Aldrich) and a flame-ionization detector. The carrier gas, helium, was delivered at a flow rate of 5 mL/min. The initial oven temperature of 60°C was maintained for 1 min, then raised to 145°C (at a rate of 20°C/min), and then increased to 185°C (at a rate of 4°C/min), before finally being held at 185°C for 5 min. Both the injector and detector temperatures were set at 250°C. Peaks were integrated with use of Atlas Lab managing software (Thermo Lab Systems).
Statistical analysis. Statistical analysis was carried out on Minitab, version 15 (Minitab Ltd.). Data presented are means 6 SEMs at baseline and end of intervention, as well as difference from baseline (D intervention or % D intervention for FISH data) for both interventions. Normality tests were performed and the FISH data were logarithmically transformed before analysis. To assess whether the order of the intervention arms had an effect on the data, baseline means were compared with use of two-sample t tests and no statistical differences were found. With the exceptions mentioned below, a general linear model was used to analyze the data. Variables specified in the model were study visit (or level of symptom), age, gender, screening variables (i.e., BMI, systolic and diastolic BP, body fat percentage, waist circumference, and alcohol consumption), habitual fiber and WG intake (based on 3DFDs from run-in period), starting intervention arm, and baseline concentration of plasma alkylresorcinols. Where effects of study visit (or level of symptom) were found (P < 0.05), further comparisons were performed with use of TukeyÕs simultaneous tests. D intervention and % D intervention data were compared with use of two-sample t tests. For the analysis of 3DFD and DCD data, a single-factor general linear model was used and further comparisons performed with use of TukeyÕs simultaneous tests. Comparisons of WG intake data from the 3DFDs, FFQs, and DCDs were performed with use of two-sample t tests. Twosample t tests were also used to compare the frequency and duration of adverse events and medication between the 2 interventions. SpearmanÕs correlation coefficients between fiber, WG intake, and variables studied were calculated and P values reported. In all cases, the level of significance was set at 5% and trends were reported at 10%. 
Results
Dietary analysis and assessment of WG intake. A habitual diet low in WG intake was a prerequisite for subjects taking part in this study, and the FFQ at screening and the 3DFD during the run-in period were used to assess it. Subjects were recruited on the basis of the FFQ. However, comparison with the 3DFD suggests that the FFQ underestimated habitual consumption of WGs by 65% (P < 0.001) (data not shown). Using data from the 3DFDs, subjects consumed on average 28 g/d of WG, which was slightly higher than the threshold of 24 g/d. In total, 13 subjects exceeded an intake of 24 g/d based on the 3DFDs. Nevertheless, the substitution of all habitual grain-based foods with the WG-containing foods provided during the WG intervention period resulted in consumption of WGs reaching 168 g/d (range: 67-335 g/d) according to the 3DFDs, or 159 g/d (range: 85-338 g/d) according to the DCDs ( Table 2 ). Bread was the major contributor to the increased WG intake among the food groups ( Table 3 ). In terms of cereals, wheat, followed by oats, was consumed to the greatest extent during the WG intervention (Table 3) . Fiber intake was greater during the WG period, but there was no effect of WG consumption on energy intake or other macronutrients ( Table 2 ). Plasma alkylresorcinols increased during the WG intervention ( Table 4 ) and were positively correlated with WG (SpearmanÕs r = 0.46, P < 0.001) and total fiber (SpearmanÕs r = 0.40, P < 0.001) from the 3DFDs and WG from the DCDs (SpearmanÕs r = 0.52, P < 0.001). However, the increase in plasma alkylresorcinols was at the lower end of the previously reported range of 142-847 nmol/L (24), and in 12 cases it did not exceed 84 nmol/L; this is relevant because alkylresorcinol concentrations range from 33 to 84 nmol/L when consuming non-WG or low-WG diets (26) . A comparison between the 12 volunteers with relatively low plasma alkylresorcinols and the rest of the subjects showed that the former consumed 9.1 g/d more WG oats and less WG wheat, rye, barley, rice, and corn by 10.0, 1.7, 0.4, 2.9, and 0.7 g/d, respectively.
Effect of WG intervention on blood biochemical markers, body composition, and BP. There was no effect of the WG intervention on plasma lipids or glucose (Table 4) . Similarly, there was no effect of the WG intervention on body weight, BMI, body fat percentage, waist circumference, or BP, although body weight (D intervention two-sample t test, P = 0.10) and BMI (D intervention two-sample t test, P = 0.08) tended to increase during the RG period and decrease during the WG intervention (Table 4) . Finally, total fiber intake was negatively correlated with body fat percentage (SpearmanÕs r = 20.24, P = 0.02), but not with WG intake or plasma alkylresorcinols.
Effect of WG intervention on fecal measurements, gastrointestinal bacteria, and SCFAs. The WG intervention had no effect on fecal pH, water content, or 24-h fecal weight (Table 4) . However, there was a trend for an increase in 24-h fecal weight during the WG intervention and a decrease during the RG intervention (D intervention two-sample t test, P = 0.08.). There was also a positive correlation between 24-h fecal weight and total fiber intake (SpearmanÕs r = 0.40, P < 0.001), but not with WG intake. There was no effect of WG consumption on the enumerated bacterial groups (Supplemental Table 3 ) or on fecal SCFAs (Supplemental Table 4 ).
Effect of WG intervention on gastrointestinal symptoms, adverse effects, and medication. The intervention had no effect on most of the gastrointestinal symptoms. However, subjects on the WG intervention experienced diarrhea/loose stool 10% more frequently than those on the RG intervention (P = 0.02) (Supplemental Table 5 ). Nevertheless, most of the subjects who experienced increased incidence of diarrhea only did so during the first days on the WG intervention, especially in cases where consumption of WGs was well over 80 g/d. Overall, however, symptoms were absent, less than usual, or usual for 85% of the recorded time during the WG arm, and 76% of the subjects completing the poststudy questionnaire cited more regular bowel movements as one of the reasons for preference of WG over RG foods. There were no differences between interventions in the types (Supplemental Figure 1) , frequency, or duration (Supplemental Figure 2) of adverse events.
Poststudy attitudes to WGs. On completion of the study, 65% of the subjects who provided poststudy data indicated a preference for WG foods, citing benefits such as improved bowel movements and appetite suppression, as well as taste, especially in the case of bread, breakfast cereals, and snacks (Supplemental Table 6 ). The majority of subjects reported that it was not difficult to achieve the required level. Bread was the most preferred source of WG, followed (in order of preference) by pasta, breakfast cereals, brown rice, and snacks. Finally, 76% of the subjects indicated an intention to continue to consume WG foods and reported having purchased WG products after the end of the study. 
Discussion
This study demonstrated that WG consumption could be dramatically increased in habitual nonconsumers or low-moderate consumers of WG with dietary advice and increased awareness and availability of WG foods. The WG intervention also resulted in a substantial shift in acceptance of WG products in habitual nonconsumers. However, although WG consumption was increased to a level exceeding many other interventions, there was no effect on body composition, overall dietary intake, fecal microbiota, gastrointestinal symptoms, or blood lipids and glucose. The current study aimed to recruit subjects with a low habitual WG intake of <24 g/d; habitual WG intake was in fact slightly higher than this at 28 g/d (as determined by the 3DFDs). Nevertheless, during the WG period, subjects increased their WG intake by 500%. Thus, the difference in intake between baseline and intervention, and between RG and WG periods, exceeded the target. This increased WG intake was accompanied by an increase in fiber intake. Although this may have been responsible for the perceived increase in satiety (10), there was no significant effect of WG consumption on intakes of energy, fat, or carbohydrate. The WG estimates based on the DCDs correlated highly with the 3DFD estimates, indicating that the majority of the WG intake during the WG period came from the provided foods.
The increased WG intake during the WG arm of the study was accompanied by an increase in plasma alkylresorcinols, which are present in rye, wheat, and barley, and broadly fulfill the criteria to act as biomarkers of intake of WG rye and WG wheat (26) . Wheat was the main contributor to WG intake (59%), with oats, rice, and corn together contributing ;40% of the WG intake. In line with published data (24) , mean plasma concentrations of alkylresorcinols were <60 nmol/L at baseline and during the RG arm, but the mean concentration after 6 wk of the WG intervention was 161 nmol/L. This is at the lower end of the previously reported range of 142-847 nmol/L (24). Because of large interindividual variation, it is difficult to exclude subjects on the grounds of noncompliance based on alkylresorcinol measurements (26) . Moreover, oats, rice, and corn are not sources of alkylresorcinols but contributed substantially to the WG intake in the current study. For these reasons subjects were not excluded from the data analysis based on plasma alkylresorcinol concentrations.
In the current study, there were no effects of WG consumption on blood lipids, glucose, body composition, or BP, although there were trends toward increased body weight and BMI during the RG period relative to the WG period. The lack of effect on body weight, BMI, waist circumference, body fat content, fasted glucose, and blood lipids is consistent with several other studies (12, 13, 15, 16, 23) , but a few studies have even reported undesirable effects of WGs on blood lipids; e.g., Tucker et al. (14) reported increased levels of LDL in healthy volunteers with the E3/E3 genotype after consumption of WG wheat sourdough bread for 6 wk compared to white bread. Additionally, Davy et al. (16) reported a trend toward an increase in TC, LDL cholesterol, and TG concentrations after consumption of high-fiber wheat for Whole grain and health 5 of 7
by guest on December 29, 2017 jn.nutrition.org 12 wk, but not after consumption of an oat cereal for the same time. However, other studies reported reductions in BP, TC, and LDL cholesterol after 6 or 12 wk of WG wheat, wheat and oats, or oat interventions (17, 18) . Variation in study design is likely to be a key factor responsible for the inconsistency. Power is also an important consideration; inconsistency in previous data and uncertainty with respect to effect size meant that it was difficult to conduct a well-justified power calculation. The sample size was therefore comparable to previous studies. However, retrospective calculations suggest that the subject number required to detect a significant impact was underestimated and as many as 80 subjects may be required for a power of 80% (two-tailed t test with 5% a error probability) for some outcome measures. In most studies, including the current study, wheat was either the sole (14, 23, 36, 37) or main (15) contributor to WG intake during the intervention. Wheat is high in insoluble and low in soluble fiber, unlike oats, corn, and barley (38) , and it has been suggested that soluble fiber improves glucose metabolism (39) and lowers TC, LDL cholesterol (40) , and BP (41) to a greater degree than insoluble fiber. Soluble fiber and b-glucan content may partly explain the beneficial effects reported after interventions with oats (16, 18, 42, 43) in comparison to wheat (14, 23, 36, 37) , although other studies have demonstrated beneficial effects of WG wheat on BP (19) and blood lipids (44, 45) in comparison to RG controls. The lack of effect in the current study may have been a result of the healthy nature of the subjects and some uncertainty about degree of compliance.
Surprisingly, there were no effects of the WG intervention on the composition of gut microbiota. However, there was a trend toward increased 24-h fecal weight during the WG intervention relative to the RG intervention, which may be attributed to fiber consumption because 24-h fecal weight was positively correlated with total fiber intake. Previous interventions using WG maize (12) or barley and brown rice (46) reported increased numbers of fecal bifidobacteria, although these studies involved the addition of single products consisting of 1 or 2 WG cereals (providing 48 or 60 g/d WG) rather than the whole-diet approach employed in the current study. It could be speculated that processing involved in the manufacturing of the WG foods used in the current study may have resulted in a lower content of indigestible, fermentable carbohydrates than the intact grain and therefore a lack of effect on bacterial populations. For example, previous research has shown that partially toasted and toasted wheat flakes did not increase numbers of lactobacilli in vitro, whereas raw wheat flakes did (47) . However, changes in Clostridium leptum were observed in a short-term WG intervention based only on commercially available products (24), suggesting it is also possible that there were small changes in specific bacterial populations, which were not detectable through use of the FISH probes, and that application of highthroughput sequencing methods would be desirable in the future.
There were no effects of WG consumption on gastrointestinal symptoms, with the exception of diarrhea/loose stool. It is well established that fiber consumption prevents loose stool and constipation by normalization of transit time (48) . However, sudden increases in fiber intake, as in the current study, may result in loose stools or even diarrhea (49) . Therefore, it is reasonable to assume, on condition that WG intake is gradually increased, that fiber intake may reach levels exceeding recommendations without any negative effect on gastrointestinal symptoms. In addition, as reported by 76% of the volunteers completing the poststudy questionnaire, more regular bowel movements may be a perceived beneficial effect of increased WG intake.
It is notable that 88% of the subjects reported better understanding of food sources and the health benefits of WGs on completion of the study and, importantly, indicated a preference for WG than RG products, citing better taste and appetite suppression as their reasons, which is in line with previous research (50) . Furthermore, the majority of subjects stated their intention to continue to consume WG products and reported having purchased WG products after completing the study.
In conclusion, a combination of dietary advice and provision of commercially available food items enabled subjects with a low-moderate habitual consumption of WGs to increase their WG intake to a mean of almost 170 g/d, exceeding the level achieved in most previous studies. However, there was little effect of WG consumption on blood biochemical markers, body composition, BP, fecal measurements, or gut microbiology. Concentrations of plasma alkylresorcinols increased during the WG period, but there was wide interindividual variation and some limitations in the use of these biomarkers as measures of compliance. Study design, type and processing of the WGs, and methodologic considerations may be key determinants of study outcome and need to be further evaluated in future studies.
